Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 1.00 |
| ▸ | CDK1 | P06493 | 6/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.75 |
| ▸ | CDK4 | P11802 | 1/20 | 0.58 |
| ▸ | CDKL1 | Q00532 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923181 | 0.93 | CDK2 (0.86) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL2924573 | 0.91 | CDK2 (0.83) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL2924335 | 0.90 | CDK2 (0.81) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL2925967 | 0.89 | CDK2 (0.80) | CDK2CDK1KCNH2 | |
| SCHEMBL2921519 | 0.89 | CDK2 (1.00) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL2924627 | 0.87 | CDK2 (0.77) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL4516321 | 0.86 | CDK2 (1.00) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL2924704 | 0.84 | KCNH2 (0.82) | CDK2CDK1KCNH2CDK4CDKL1 | |
| Lithium Ion SCHEMBL2924705 | 0.83 | KCNH2 (0.81) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL2926867 | 0.83 | KCNH2 (0.77) | CDK2CDK1KCNH2CDK4CDKL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044058-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | claimed |
| US-20100240686-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-23 | — | — | US | claimed |
| EP-2044058-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2009-04-08 | — | — | EP | claimed |
| WO-2007148070-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | claimed |
| EP-2044058-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20100240686-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240686-A1 | CHEMICAL COMPOUNDS | CCNI, CDKN1A, CCNB1 | CDK2 11/4885CDK1 12/4885KCNH2 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.